ResultsCNBC-TV18
Senores Pharma expects to cross ₹3,000 crore revenue target ahead of schedule
Positive+62
GreyOak summary
Senores Pharmaceuticals anticipates surpassing its ₹3,000 crore revenue goal within three to four years, potentially earlier than planned. Growth is driven by new US product launches and subsidiary operations, with 70% of revenue expected from the US market. The company plans to commercialize 116 additional products and improve EBITDA margins.
What it affects
- Senores PharmaceuticalsSENORESPositive +62
Revenue target of ₹3,000 crore expected soonerRolling sentiment Positive +43
Source
Read the original at CNBC-TV18More Senores Pharmaceuticals news
No other recent stories about Senores Pharmaceuticals.
All Senores Pharmaceuticals news →